Atrovent
(ipratropium)Phase 2Small molecule
Boehringer IngelheimThis medication is a bronchodilator that relaxes and opens the airways in the lungs to make breathing easier. It is used to prevent wheezing, shortness of breath, coughing, and chest tightness in people with chronic lung diseases like COPD, chronic bronchitis, and emphysema.[1] Atrovent is currently being investigated across 5 indications[3], with its most advanced program in Phase 2.[1]
Atrovent is one of 71 small molecule programs targeting Status Asthmaticus. It is currently in Phase 2.
5
Indications
16
Total Trials
1
Active Trials
70
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Atrovent
Boehringer IngelheimPhase 2
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Asthma2 trials
Acute bronchitis1 trial
Status Asthmaticus1 trial
10 more indications
Pilot Study1 trial
Combination Therapy1 trial
Chronic Obstructive Pulmonary Disease1 trial
Efficacy and Safety1 trial
Function1 trial
Cough Suppression1 trial
A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy
Not yet recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT06376942·1,050 enrolled
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Dec 29, 1986
ATROVENT
NDA NDA019085
Sep 29, 1993
ATROVENT
NDA NDA020228
Oct 20, 1995
ATROVENT
NDA NDA020393
Oct 20, 1995
ATROVENT
NDA NDA020394
Nov 27, 2004
ATROVENT HFA
NDA NDA021527
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ipratropium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
Patent Landscape[5]
Patent Cliff
Jan 17, 2030
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8474447Jan 17, 2030